
Engineering a full life-sciences pipeline
How Mississauga’s life-sciences sector is emerging as a bridge between lab and market
When scientists first drove through the rolling fields west of Toronto towards AstraZeneca’s new research facility in the early 1960s, few would have guessed they were heading into what would become one of Canada’s most important life-sciences hubs. At the time, Mississauga was valued for space and proximity: affordable land, easy highway access and a short drive to the airport.
Over time, multinationals from every part of the pharmaceuticals supply chain clustered around what became known as “Pill Hill”, anchoring manufacturing, research and clinical operations as the city grew around them. Today, Mississauga is home to more than 500 life-sciences firms, employing around 27,000 skilled workers across pharmaceuticals, biotech, medical devices and contract manufacturing. By 2020, it had emerged as one of Canada’s leading destinations for life-sciences investment, attracting firms such as Roche and GSK. AstraZeneca has continued to expand its presence in the region, committing C$820m in 2025 to new research capacity spanning oncology, immunology, infectious disease and digital health.
The city’s growth reflects not only scale but circumstance. Positioned between Toronto’s research hospitals and the global reach of Pearson International Airport—located in Mississauga itself—it has evolved into a practical point of connection, linking research, development and international markets.
Increasingly, Mississauga is a location where the sector comes together through industry events that shorten decision-making cycles. The city has come to prominence as governments and companies alike are reassessing where critical biomedical research, manufacturing and supply chains should be located.
“This is a place that’s seen extraordinary development around a new industry, new technology and rapid population growth,” says Alexandra Gillespie, principal at the University of Toronto Mississauga (UTM), one of the University of Toronto’s three campuses and a key pipeline in terms of research, talent and start-ups for the region.
But translating research strength into commercial scale has required creative solutions. Life sciences is capital-intensive, lab space in the region is scarce and promising firms still face strong incentives to relocate once they begin to grow. Wet labs especially are critical in life sciences, as these often determine whether companies can survive the leap from discovery to development.
"This is a place that’s seen extraordinary development around a new industry, new technology and rapid population growth."
Alexandra Gillespie, principal at the University of Toronto Mississauga (UTM)

Bridging the lab gap
One response has been to meet start-up companies where they are at in their journey. In Mississauga, that process increasingly begins on campus. SpinUp, UTM’s wet lab incubator, opened in 2024 to give early-stage researchers a route out of the laboratory and into the market. One of its tenants, Maman Biomedical, is developing a needle-free hormone patch for fertility treatments.
The founders first tested prototypes at home. “When they started experimenting on this technology, they were doing it in their own kitchen in their own apartment,” says Ms Gillespie. “We were able to provide highly affordable university space, access to students, access to other professors and a whole startup ecosystem.”
Once ideas take shape at SpinUp, they can graduate to SPEC Labs, a not-for-profit facility focused on later-stage start-ups that is in development, and then scale alongside the international pharmaceutical industry already present on Mississauga’s Pill Hill.
SPEC Labs provides ready-to-move-in wet labs, designed to keep companies from falling through the cracks. “Shared lab space is critical at this stage because it helps keep costs down,” says Sam Ricchezza, chief alliance officer at SPEC Labs. “By sharing equipment and resources, companies can focus capital on advancing their science rather than duplicating infrastructure.”
For firms moving beyond incubation but not yet ready for long leases, that access can determine whether they stay in Canada or leave. HDAX Therapeutics, a precision medicine startup spun out of UTM in 2021, has already filed two patents for a more powerful treatment for chronic nerve damage. Neuropeutics, also spun out of the university, is developing targeted therapies for neurodegenerative conditions such as ALS, Alzheimer's and Parkinson's diseases.
“We’re seeing more students engaged in advanced research, and that’s translating into a stronger pipeline of innovation,” says Mr. Ricchezza. “More ideas are maturing, and more of them are being spun out into companies.”

The advantage of proximity
Beyond laboratory space, Mississauga is also rich in the less visible infrastructure required to compete globally. Contract development and manufacturing is supported by firms such as Eurofins CDMO Alphora, temperature-controlled logistics by global operators including Kuehne+Nagel, and regulatory navigation by specialist advisers such as Q&C Services. Together, these capabilities create a tightly connected environment in which life-sciences firms can advance without leaving the city.
That density, combined with a robust conference ecosystem, including convention centres, major hotels and Canada’s largest airport, has made Mississauga a practical hub for the life-sciences sector, where people can collaborate on work that would otherwise be spread across institutions and geographies. Industry meetings and scientific workshops, often hosted around SpinUp, SPEC Labs or the city’s established pharmaceutical campuses, bring together researchers, start-ups, manufacturers and policymakers at moments when companies are deciding whether to scale locally or relocate.
Mississauga may still lack the global name recognition of longer-established life-sciences centres. But its role is becoming clearer: a place where interaction is easier. In a field shaped by collaboration, that can make a difference. “Progress happens when people cross paths,” says Mr. Ricchezza. “The more often that happens, the more ideas you generate, and the more opportunities it creates.”
The result is a steady flow of innovation, shaped by Mississauga’s ability to keep research, manufacturing and decision-making within easy reach of one another.
"Progress happens when people cross paths. The more often that happens, the more ideas you generate, and the more opportunities it creates."
Sam Ricchezza, chief alliance officer at SPEC Labs

